Skip to content
Announcement:

Webinar: hear from our 3 panelists discussing regulatory, technology, and scientific perspectives to accelerate your compound through the clinical development pipeline with predictive retina models

Updates: Products

aProximate™ Assay-Ready Plates launch poster.
18th January, 2023

New Product Launched – aProximate™ 96-well Assay-Ready Plates

Get our aProximate™ PTCs to your lab anywhere in the world (24 & 96-well plates) aProximate™ Assay-ready plates contain freshly isolated primary human proximal tubule cells (PTCs). The plates are…

Read update
A massively zoomed in image for the slider
12th October, 2022

First podocyte toxicity assay now commercially available

Damage to the glomerular filtration barrier (GFB) results in protein leakage from the plasma into the urine, so called proteinuria, and is associated with loss of kidney function, which…

Read update
Glomerulus
11th August, 2022

How a glomerulus in vitro model can accelerate drug development

The glomerulus is the part of the kidney involved in the filtration of solutes and waste from the blood. Damage to the glomerulus by diabetes mellitus, hypertension, glomerulonephritis, or…

Read update
24 Plate Product
13th July, 2022

New Product Launched – aProximate™ Assay-Ready Plates for transporter studies

aProximate™ Assay-ready plates contain freshly isolated primary human proximal tubule cells (PTCs). The plates are provided in an easy to use 24-well Transwell® format. Visit our product page…

Read update
Retinal organoids
28th April, 2022

Retinal Organoids for Drug Discovery

Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…

Read update
Newcells Biotech
5th November, 2021

iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery

What retinal models are available for drug development? Animal models are the most frequently used for investigating safety and efficacy of ophthalmic drugs. However, due to several key physiological differences,…

Read update
12th October, 2023

Imaging propels our kidney assays to the next level

We recently expanded our imaging capability with the purchase of an ImageXpress Pico high content imaging (HCI) system from Molecular Devices. Since then, our technical teams have been busy…

Read update
29th August, 2023

Latest Advances in CAR-T Therapy with novel HLA-typed in vitro cell tools

CAR-T Therapy CAR-T Therapy is a form of immunotherapy that harnesses the power of the patient’s immune system to target and eliminate cancer cells. It involves ex-vivo genetic engineering of…

Read update
28th July, 2023

MPS summit highlights

About the conference: MPS summit The MPS summit is a small but buzzing conference, where scientists from the pharma industry, academia and microchip manufacturers gather to discuss the latest advances…

Read update
30th June, 2023

3rd ILD Summit Highlights

About the conference : ILD Summit The ILD Summit is a niche industry dedicated conference focussed on advancing therapies for progressive fibrosing interstitial lung diseases (ILD). This year’s conference was the…

Read update
Pulmonary toxicity – a challenge for drug and chemical development
16th June, 2023

Pulmonary toxicity – a challenge for drug development

Despite the common assumption that adverse drug reactions usually affect the kidney and liver, over 600 medications have been reported to induce lung toxicity.1 Due to the large surface area,…

Read update
5th May, 2023

ARVO Highlights

About the conference: ARVO The ARVO conference took place in the New Orleans Ernest N. Morial Convention Center.  With over 10 000 attendees, the venue was absolutely huge. If you…

Read update

Get our latest updates straight to your inbox